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Abstract
Transcriptional regulation is essential for any gene expression including microRNA expression. MiR-1-1 and
miR-133a-2 are essential microRNAs (miRs) involved in cardiac and skeletal muscle development and diseases.
Early studies reveal two regulatory enhancers, an upstream and an intragenic, that direct the miR-1-1 and
miR-133a-2 transcripts. In this study, we identify a unique serum response factor (SRF) binding motif within the
enhancer through bioinformatic approaches. This motif is evolutionarily conserved and is present in a range of
organisms from yeast, flies, to humans. We provide evidence to demonstrate that this regulatory motif is SRF-
dependent in vitro by electrophoretic mobility shift assay, luciferase activity assay, and endogenous chromatin
immunoprecipitation assay followed by DNA sequence confirmation, and in vivo by transgenic lacZ reporter mouse
studies. Importantly, our transgenic mice indicate that this motif is indispensable for the expression of miR1-1/133a-2
in the heart, but not necessary in skeletal muscle, while the enhancer is sufficient for miR1-1/133a-2 gene expression
in both tissues. The mutation of the motif alone completely abolishes miR-1-1/133a-2 gene expression in the animal
heart, but not in the skeletal muscle. Our findings reveal an additional architecture of regulatory complex directing
miR-1-1/133a-1 gene expression, and demonstrate how this intragenic enhancer differentially manages the
expression of the two miRs in the heart and skeletal muscle, respectively.
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Introduction
Transcriptional regulation is a pivotal and precise regulatory
mechanism that spatially and temporally controls all gene
expression including microRNA genes. Transcription factors
play central roles in the transcriptional regulation processes,
leading to the activation, inhibition, or tissue-specific
expression of the target genes. Serum response factor (SRF) is
a member of an ancient family of DNA-binding proteins. It
contains a highly conserved DNA binding/dimerization domain
of 90 amino acids, termed the MADS box [1]. SRF is a key
regulator of immediate early gene expression and of terminal
muscle differentiation [2,3]. A large number of cardiac, skeletal,
and smooth muscle contractile protein genes contain CArG box
sequences, an SRF DNA binding site known as serum
response element (SRE), in their promoter regions [4,5]. These
muscle-specific genes are dependent upon single or multiple
CArG boxes as determinants of strong and weak binding sites
[3,6,7]. Besides directly binding to the SRE, SRF also serves
as a platform to recruite other muscle regulatory proteins, such
as NK2 homeobox 5 (NKx2.5), to enhance its transcriptional
regulation [7-11].
Analyses of SRF-null mice and null ES cells reveal severe
impediments in mesoderm formation, heart formation, and the
expression of SRF-regulated genes [12-16]. Cardiac-specific
ablation of the murine SRF gene results in embryonic lethality
due to cardiac insufficiency during chamber maturation and
blockage in the transcription of downstream gene targets
[9,11]. Mice lacking SRF expression in skeletal muscle show
severe hypoplasia and fail to grow [8]. All of these studies
demonstrate that the diversified regulatory effects of SRF on
different tissues are highly dependent on the target gene
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promoters and enhancer regions. Identification of regulatory
motifs of SRF provides fundamental information for the target
gene manipulation and regulation. In this study, we identify a
unique, highly conserved CArG motif located in the intragenic
enhancer region of two microRNAs, miR-1-1 and miR-133a-2.
The binding of SRF to this SRE site activates transcription of
the bicistronic, precursor RNA encoding the miR-1-1/133a-2
gene. Furthermore, we demonstrate that this new SRE motif is
the critical site by directing the expression of the
miR-1-1/133a-2 gene in cardiac but not in skeletal muscle,
which reveals a new regulatory element to differentiate
miR-1-1/133a-2 expression between cardiac and skeletal
muscle at the transcriptional level. Since miR-1-1/133a-2 is a
pair of muscle-specific miRNAs with multiple functions in both
cardiac and skeletal muscle proliferation and differentiation, our
findings provide new information on cardiac-specific regulation
of miR-1-1/133a-2 expression.
Materials and Methods
Cell Culture, Plasmid Constructs, and Gene Transient
Transfection
Mouse myoblast C2C12 cells were cultured in DMEM
medium with 10% FBS. SRF and NKx2.5 expression vectors
were generated as described previously [17]. All transient
transfections were conducted in C2C12 cells (1×105 cells/well
in a 12-well plate for a confluent cell layer) using Lipofectamine
2000 in the Opti-MEM reduced serum medium (Invitrogen).
Electrophoretic mobility shift assay (EMSA)
The 32P-labeled 20 bp long DNA duplex containing one SRE
from the intragenic enhancer region of the miR-1-1/133a-2
gene was used as a probe. The positive SRE probe was
derived from a skeletal β-actin promoter containing one SRE as
described previously [18]. A mutant SRE probe was used to
validate the specificity of binding. The probe sequences were
as follows (5’ to 3’): SRE, ATGCCCAGATATGGCCACAG/
CTGTGGCCATATCTGGGCAT; and mutant SRE,
ATGCAAAGATATAACCACAG/CTGTGGTTATATCTTTGCAT.
Experiments examining the supershift by the anti-SRF antibody
(G20, Santa Cruz, CA) and competition with unlabeled probe
were conducted to verify the SRF-DNA interaction. Nuclear
extracts were used for each experiment.
Chromatin immunoprecipitation (ChIP) assay
To define the interaction of SRF with the intragenic SRE
regulatory motif in vivo, a ChIP assay was performed as
described previously [19]. After the SRF expression vector or
the SRF specific siRNA (siSRF) (Thermo Scientific Dharmacon
RNAi technologies, L-050116-01-0005, Lafayette, CO) was
transfected into C2C12 cells for 36 h, cells were gently fixed
with formaldehyde and lysed by sonication. The specific SRF-
DNA complex was immunoprecipitated using the anti-SRF
antibody. The identity of the DNA fragment isolated from the
SRF complex was determined by PCR using primers specific
for the intragenic regulatory element, which presumably
contains the SRF binding site. The PCR primers for the SRE
were as follows (5’ at 4965 nucleotide to 3’ at 4770 nucleotide):
CCTGTCATGGGGGTTCTATG/
CAGGACAGCTGAGAATGCAG. Final PCR product was then
sequenced to confirm the presence of the CArG motif (Lone
star Labs, TX). The additional four pairs of non-specific PCR
primers (NS-P1 to NS-P4) upstream and downstream of the








The quantitative ChIP assay was performed by using the
Abcam ChIP Kit (ab500, UK), and the results were normalized
with each histone pull-down Ct value.
Luciferase assay
To determine the functional significance of the CArG
regulatory motif, the 4.4 kb intragenic enhancer region of
miR-1-1/133a-2 containing the SRE was subcloned into a
pGL3-basic vector expressing a luciferase reporter gene
(Promega) by KpnI and SmaI. A similar vector with the mutant
SRF binding site (AAAGATATAA) was constructed as a mutant
reporter. Generation of the SRF expression vector and
transient transfection were described previously36. The
luciferase assay was conducted 36 h post transfection, and 20
of 60 μl of the lysis supernatant were used for the
measurement of luciferase activity by a Monolight 3010
luminometer (Pharmingen). Each sample was measured twice.
All results were normalized to β-galactosidase activity (MRX
Revelation, DYNEX Technologies, Inc., Chantilly, VA).
Generation and analysis of transgenic mice
To delineate the SRF-dependent regulatory element within
the intragenic enhancer, we made the transgenic mice
expressing the LacZ reporter gene to test its function in vivo.
The generation of the transgenic mice was described
previously [18]. Briefly, the highly conserved 4.4 kb intragenic
enhancer region of miR-1-1/133a-2 containing the SRE was
subcloned by KpnI and SmaI into the pBS-KS-Hsp68-LacZ
vector driven by the Hsp68 promoter. The vector was used for
a pronuclear microinjection with FVB background, and a
parallel process was performed by using the same enhancer
with the mutated SRF binding site (AAAGATATAA). The tissue-
specificity and expressional levels are dependent on the
intragenic regulatory motif. The F0 transgenic mice were
analyzed at embryonic stage E10.5 and E11.5 by β-
galactosidase staining. Positive lacZ blue was used for
genotyping purposes. All experiments with animals were
approved by the Institutional Animal Care and Use Committee
of the Texas A&M Health Science Center–Houston.
Statistical analysis
Data were expressed as means + the standard errors of the
means. All experiments were conducted at least three times. In
two-group comparisons, the unpaired, two-tailed student’s t test
Transcriptional Regulation of MicroRNA-1-1/133a-2
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was used (SigmaPlot, version 11.0). A value of P < 0.05 was
considered statistically significant.
Results
Identification of a potential SRF-dependent regulatory
motif within the intragenic enhancer of miR-1-1/133a-2
Using the Silico database (http://microRNA.sanger.ac.uk),
we analyzed 9.2 kb of genomic sequence between the miR-1-1
and 133a-2 genes, the intragenic enhancer region for the two
miRs. We found one potential SRF binding site, SRE (Figure
1A). A comparison of genomic sequences across species
revealed that this SRE site was highly conserved among
species ranging from yeast to humans. The analysis also
showed a conserved NKx2.5 binding site within the intragenic
enhancer. Next, we verified the functional role of this
perspective motif in the miR-1-1/133a-2 gene transcription
regulation in vitro and in vivo.
SRF binds to the CArG motif in the miR-1-1/133a-2
intragenic enhancer region in vitro
To determine whether SRF binds to the identified SRE in the
intragenic enhancer region of miR-1-1/133a-2, a
comprehensive EMSA assay was performed (Figure 1B). A
band shift was detected with the addition of the 32P-labeled
probe containing the perspective SRE and nuclear extract
(Figure 1B lane 3), while no SRF binding to the mutant SRE
probe was observed, thus validating the binding specificity
(Figure 1B lane 4). A supershift band was obtained by adding
the anti-SRF antibody (Figure 1B lane 5), confirming the SRF-
SRE interaction. Finally, an excess of unlabeled wild-type
probe was included in the SRF-SRE binding reaction, which
resulted in the abolishment of the band shift (Figure 1B lane 6).
This experiment confirmed that SRF was able to bind to the
SRE motif in the miR-1-1/133a-2 intragenic enhancer region in
vitro.
SRF interacts with the miR-1-1/133a-2 intragenic
enhancer region in vivo
To verify that SRF interacts with the miR-1-1/133a-2
intragenic enhancer region through the SRE in vivo, a ChIP
assay was performed (Figure 2A). The specific SRF-DNA
complex was immunoprecipitated using an anti-SRF antibody
(Figure 2A left panel). Sequencing analysis revealed that the
DNA fragment isolated from the complex with SRF contained
part of the miR-1-1/133a-2 intragenic enhancer sequence with
the predicted SRE site (Figure 2 right panel); therefore
confirming the interaction of SRF with the CArG box in vivo in
the miR-1-1/133a-2 intragenic enhancer region.
To rule out any possible false positive ChIP result and to
further verify the specificity of the identified SRE, we conducted
two quantitative ChIP assays. The first one was performed
when SRF expression was knocked down by siSRF (Figure
2B). The downregulation of SRF resulted in a dramatic
decrease in the SRE nucleotides pulled down from the
knockdown cells (Figure 2C). The second quantitative ChIP
assay was conducted by using four pairs of PCR primers
chosen from upstream and downstream of the SRE site. The
qPCR results showed that these primers failed to detect the
SRE motif. Together, the experiments validated the specificity
of the SRE motif and demonstrated the interaction of SRF with
the CArG box in vivo.
SRF activates the miR-1-1/133a-2 intragenic enhancer
To evaluate the functional significance of this SRE, a 4.4-kb-
long duplex of the intragenic enhancer containing the SRE was
subcloned into a luciferase reporter vector. The chimeric vector
can express luciferase as a reporter under miR-1-1/133a-2
intragenic enhancer control. The effect of SRF on luciferase
expression can be detected from the changes in luciferase
activity. We found that co-transfection of the reporter and SRF-
expressing vectors led to a >18-fold increase in luciferase
activity compared to the baseline control without SRF co-
expression (Figure 3). In a parallel experiment, the proactive
effect of SRF on the miR-1-1/133a-2 intragenic enhancer was
attenuated by the mutation of the SRF binding site, SRE, in the
enhancer. Meanwhile, the increased luciferase activity was
further enhanced by SRF and NKx2.5 co-transfection, and this
enhancement was again lessened by the mutation of the SRE.
This experiment indicates that miR-1-1/133a-2 is regulated by
SRF.
The intragenic enhancer directs miR-1-1/133a-2 gene
expression in heart and skeletal muscle, and the SRE in the
enhancer is responsible for a differential expression of
miR-1-1/133a-2 in the heart but not in skeletal muscle
Finally, we investigated the role of this SRF-regulated motif
in the tissue specificity of miR-1-1/133a-2 expression. Two
transgenic mouse lines expressing the reporter gene, LacZ,
driven by the miR-1-1/133a-2 enhancer containing the wild-
type SRE and the mutant SRE, respectively, were generated.
We dissected the mice at two time points, E10.5 and E11.5.
We found that the wild-type enhancer was sufficient to direct
LacZ gene expression in both cardiac and skeletal muscle
regions (Figure 4A and 4B). However, the enhancer with the
mutant SRE abolished LacZ gene expression in the mouse
heart but not in skeletal muscle (Figure 4C and 4D). To
observe the detailed expression location of the LacZ reporter
gene, the whole embryos were sectioned. We found that lacZ
staining was restricted in cardiac ventricles, atria, and somite
myotome areas in wild-type mice (Figure 4E-4F and 4I-4J). The
mutation of SRE in the enhancer only diminished LacZ reporter
expression in cardiac ventricles and atria but not in the somite
myotomes (Figure 4G-4H and 4K-4L). This result suggests that
the SRF-regulated motif is obligatory for cardiac-specific
expression of miR-1-1/133a-2.
Discussion
MiR-1 and miR-133 are muscle-enriched microRNAs, and
they have been demonstrated as critical factors involved in
both cardiac and skeletal muscle development and diseases
[20-25]. Given that individual microRNAs regulate potentially
dozens of genes, functions of miR-1 and miR-133 in cardiac
muscle and skeletal muscle can be quite distinct [23,26,27].
Mice with miR-1-2 deletion develop ventricular septal defect
Transcriptional Regulation of MicroRNA-1-1/133a-2
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Figure 1.  Analysis of miR-1-1/133a-2 intragenic enhancer region.  (A) Representative sequence alignments between miR-1-1
and miR-133a-2 genes among species. One putative and highly conserved serum response factor (SRF) binding site (SRE) along
with one NK2 homeobox 5 (NKx2.5) binding site were suggested by bioinformatic predictions. (B) A comprehensive electrophoretic
mobility shift assay (EMSA) demonstrated specific interaction between SRF and this SRE motif in vitro. Ab: antibody. WT: wild-type.
Competitor: unlabeled WT probe.
doi: 10.1371/journal.pone.0075470.g001
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(VSD), cardiomyocyte hyperplasia, and abnormal
electrophysiology [27]. While the deficiency of miR-133a leads
to cardiomyocyte proliferation and VSD. For skeletal muscle,
miR-1 facilitates myogenesis, and miR-133 promotes myoblast
proliferation [20]. Both miR-1 and miR-133 also participate in
cardiomyopathy development including cardiac hypertrophy
[25,28], cardiac fibrosis [29,30], and arrhythmia [30,31].
Understanding tissue-specific transcription regulation will
provide a foundation for us to manipulate the expression of the
two miRs spatially.
There are two copies of miR-1 and miR-133, the
miR-1-2/133a-1 and miR-1-1/133a-2. The transcriptional
regulation and the enhancer dissection of miR-1-2/133a-1 have
been investigated [32]. In this study, we focused on
miR-1-1/133a-2. MiR-1-1/133a-2 are transcribed as bicistronic
transcripts on mouse chromosome 2, and they can be
transcriptionally regulated by two regulatory loci, which have
been dissected by two independent studies [26,32]. One
regulatory locus is located upstream of miR-1-1 [26], while the
other locus is the 9.2 kb intragenic enhancer located between
MiR-1-1 and miR133a-2 (Figure 1A) [32]. The upstream and
the intragenic enhancers contain multiple cis-regulatory
elements allowing different transcription factors, including SRF,
myocyte enhancer factor 2 (MEF2), and E-box binding factors,
to bind. The upstream enhancer study showed that the MEF2
site is mainly responsible for skeletal muscle expression, while
this regulatory locus relies on SRF for cardiac expression [26].
Meanwhile in the analysis of the intragenic enhancer,
Figure 2.  The putative SRE motif located in the intragenic enhancer of miR-1-1/133a-2 was verified by the chromatin
immunoprecipitation (ChIP) assay with sequencing assessment in vivo.  The cell chromatins were extracted from C2C12 cells
transfected with either SRF expression vector or siRNA specific for SRF, and the SRF-SRE complexes were pulled down by the
anti-SRF antibody. A. The oligonucleotides containing the SRF-binding site were detected (left panel). The PCR product was
sequenced and the sequence matched with the enhancer (right panel). B. Quantitative PCR showed that SRF knockdown was
achieved. C. Quantitative ChIP assays showed that loss of SRF resulted in decreases in the SRF-SRE complexes, and non-specific
PCR primers failed to detect the SRE motif. SRE-P: specific primers for SRE; NS-P: non-specific primers upstream and downstream
of the SRE site.
doi: 10.1371/journal.pone.0075470.g002
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miR-1-1/133a-2 expression in skeletal muscle is determined by
the intact MEF2 motif [32]. In this study, we expand this
Figure 3.  Analysis of miR-1-1/133a-2 intragenic enhancer
region containing the SRE motif by luciferase
assay.  Empty bar represents reporter vector activity directed
by the enhancer with the wild-type SRE motif. Solid bar
represents reporter vector activity directed by the enhancer
with the mutant SRE motif. SRF increased the luciferase
reporter gene activity, and the addition of NKx2.5 facilitated
SRF functional activity. Mutation of the SRF binding site
resulted in a reduction of the reporter gene activity. The data in
each group represents the averages of three experiments with
a total of six measurements. Statistical significance was
determined by unpaired, two-tailed student’s t test. Data are
means ± S.E.
doi: 10.1371/journal.pone.0075470.g003
observation and provide evidence that one evolutionarily
conserved SRF binding site in the intragenic enhancer
determines the cardiac-specific expression of miR-1-1/133a-2.
Genetic deletion of the SRF binding motif eliminates the
intragenic enhancer-directed lacZ expression in the heart but
not in somites, consistent with the role of the SRF-regulated
motif in the upstream enhancer.
The result from our study adds an additional piece of
information into this transcriptional complex that drives the
expression of two important, muscle-specific microRNAs. In
combination with the other two studies, it is intriguing to realize
that cells carry two sets of very similar regulatory complexes,
which may suggest several biological significances but not a
means of waste. First, the redundancy of transcriptional activity
may guarantee a faithful completion of transcriptional
regulation for any essential genes even under stress
conditions. Secondly, an additional enhancer could function as
a backup or a reinforcement to secure the expression as well
as the expression patterns of critical genes. Finally, multiple
transcriptional motifs may potentiate gene regulation to achieve
fine-tuning of temporal and spatial controls of gene expression.
Given the requisite role of miR-1 and miR-133 in cell survival
and development, it is convincing to believe that the redundant
transcription complexes directing miR-1 and miR-133a
expression are elegantly developed to ensure cells to survive
under evolutionary pressure.
Finally, the pathophysiological consequence of the disruption
of SRF factor has been demonstrated to contribute to heart
failure in both humans and animals. Under stress conditions,
SRF can be cleaved into a dominant negative factor that
represses its downstream target gene expression, leading to
cardiac dysfunction [17]. Given the importance of miR-1 and
miR-133 in various cardiomyopathy developments, such as
cardiac hypertrophy, understanding the precise control of SRF-
mediated microRNA gene regulation in the heart will provide an
additional perspective for the treatment of SRF dysfunction-
mediated cardiomyopathy.
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Figure 4.  The assessment of miR-1-1/133a-2 intragenic enhancer using the transgenic mice expressing the reporter gene,
LacZ, and driven by the intragenic enhancer.  β-Galactosidase staining (blue) was performed on embryos (A-D) and the embryos
were sectioned for detailed analysis (E-L). The enhancer containing wild-type SRE directed the LacZ gene expression in heart and
somite areas (A, E and I). Close-up of β-Galactosidase staining showed the cardiac-specific expression of lacZ. (B, F and J) The
enhancer containing the mutant SRE directed the LacZ gene expression in somite areas but not in the heart (C, G and K). Close-up
of β-Galactosidase staining displayed the abolishment of lacZ expression in heart (D, H and L). Embryos were at E10.5 (A-H) and
E11.5 (I-L). HR: heart. lv: left ventricle. rv: right ventricle, la: left atrium. ra: right atrium, m: somite myotomes. White arrows indicate
somite myotomes.
doi: 10.1371/journal.pone.0075470.g004
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